A10 Networks, Inc. (NYSE:ATEN) announced cloud-ready light-weight set of container-based solutions

A10 Networks, Inc. (NYSE:ATEN) has announced a cloud-ready, light-weight set of container-based solutions to provide secure application services. They offer up to 200 Gbps of throughput for A10 Networks’ Thunder Application Delivery Controller, Carrier-Grade Networking and Convergent Firewall products.

The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Insider ownership for the ATEN is 0.90%. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. The Institutional ownership for the ATEN is 67.30%.

Insider trading is the buying or selling of any publicly traded company’s stock and this can be done by someone who has non-public, material information about that ATEN. Insider trading can be illegal or legal depending on when the insider makes the trade. It is illegal when the material information is still non-public. The insider transactions of the company (6-month change in insider ownerships) for the A10 Networks, Inc. (NYSE:ATEN) is -4.81%.

Institutional transactions is the amount of a A10 Networks, Inc. (NYSE:ATEN)’s available stock owned by mutual or pension funds, insurance companies, investment firms, private foundations, endowments or other large entities that actually manage the funds on the behalf of others, so its an interesting element for the traders to note it, and the Institutional ownership for the ATEN is 6.08%.

[finviz ticker=ATEN]

A Technology sector firm, A10 Networks, Inc. (NYSE:ATEN) stock gained 1.17% on Tuesday and when day-trade ended the stock finally concluded at $6.92 and number of shares that changed hands during the day are 544857. The number of shares ATEN stock currently held by all its shareholders are 75.31 and floated shares, the number of shares are available for trading in an open market on last trading day are 55.01. The average volume of shares for 3 months is 395.60 and ATEN stock value has moved between $5.49 – 7.44 in last one year.

The A10 Networks, Inc. (NYSE:ATEN)’s latest earnings date is 7/25/2019. The Gross margin is the difference between the revenue and the cost of goods sold (COGS), divided by revenue. In other words, Gross Margin is a percentage value, while Gross Profit is a monetary value. The valuable gross margin for A10 Networks, Inc. (NYSE:ATEN) is 77.60% and the profit margin is -8.70% and the stock has gained 10.90% in 2019 to date.

A10 Networks, Inc. (NYSE:ATEN)’s monthly stock performance is 15.14%, the quarterly performance is -2.81%, the half year performance is calculated as 10.90%. The yearly performance of ATEN is 11.08%.

The higher the volatility, the riskier the security. For example, when the stock market rises and falls more than one percent over a sustained period of time, it is called a “volatile” market, if the stock price stays relatively stable, the security has low volatility. The A10 Networks, Inc. (NYSE:ATEN) weekly volatility is measured as 2.13% and monthly volatility measured as 2.34%.

Return on assets (ROA) is a main indicator of how profitable a company is relative to its total assets. ATEN return on assets is -8.80%, the return on equity (ROE) of the A10 Networks, Inc. (NYSE:ATEN) is -20.30%, while the most important return on investment is calculates as a percentage and is typically used for personal financial decisions, and ATEN return on investment is -27.70%.

The price to sales ratio is 2.23, and price to book ratio is 5.36, price to cash per share ration is 4.24.

Analysts mean target price for A10 Networks, Inc. (NYSE:ATEN) is $9.00 while analysts mean recommendation is 3.00. The current share price indicates that stock is -7.24% away from its one year high and is moving 25.59% ahead of its 52-week low. ATEN’s distance from 20 day simple moving average is 7.31% and distance from 50-Day simple moving average is 7.34%.

See also  FDA approved Pfizer Inc. (NYSE:PFE) oncology biosimilar Zirabev

Leave a Reply